Ardelyx Inc (ARDX)
9.185
+0.02
(+0.27%)
USD |
NASDAQ |
May 07, 10:52
Ardelyx Gross Profit (TTM): 135.72M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 135.72M |
December 31, 2023 | 106.66M |
September 30, 2023 | 118.39M |
June 30, 2023 | 73.95M |
March 31, 2023 | 57.49M |
December 31, 2022 | 48.04M |
September 30, 2022 | 8.054M |
June 30, 2022 | 4.973M |
March 31, 2022 | 3.898M |
December 31, 2021 | 9.097M |
September 30, 2021 | 9.873M |
June 30, 2021 | 11.41M |
March 31, 2021 | 11.80M |
Date | Value |
---|---|
December 31, 2020 | 7.426M |
September 30, 2020 | 7.871M |
June 30, 2020 | 7.571M |
March 31, 2020 | 5.894M |
December 31, 2019 | |
September 30, 2019 | |
June 30, 2019 | |
March 31, 2019 | |
December 31, 2018 | 2.141M |
September 30, 2018 | 35.66M |
June 30, 2018 | 35.49M |
March 31, 2018 | 35.46M |
December 31, 2017 | 33.60M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
3.898M
Minimum
Mar 2022
135.72M
Maximum
Mar 2024
36.95M
Average
9.873M
Median
Sep 2021
Gross Profit (TTM) Benchmarks
Nektar Therapeutics | 56.35M |
Rigel Pharmaceuticals Inc | 109.77M |
Omeros Corp | -- |
Vistagen Therapeutics Inc | -- |
Karyopharm Therapeutics Inc | 141.09M |